Patents Assigned to ABLIVA AB
  • Succinate prodrug, compositions containing the succinate prodrug and uses thereof
    Patent number: 12162824
    Abstract: The present invention provides a novel isolated succinate prodrug as the free compound or a salt, hydrate, solvate or complex thereof being cell permeable and aimed for increasing the ATP-production in mitochondria. The compound is useful in the medical treatment of a range of diseases, in nutritional supplements, nutricosmetics and in cosmetics.
    Type: Grant
    Filed: September 14, 2022
    Date of Patent: December 10, 2024
    Assignee: ABLIVA AB
    Inventors: Magnus Joakim Hansson, Alvar Grönberg, Mats Eskil Elmér, Mark Richard Farmery, Steven James Moss, Lee Robert Webster, Matthew Alan Gregory
  • Succinate prodrug, compositions containing the succinate prodrug and uses thereof
    Patent number: 11565998
    Abstract: The present invention provides a novel isolated succinate prodrug as the free com-pound or a salt, hydrate, solvate or complex thereof being cell permeable and aimed for increasing the ATP-production in mitochondria. The compound is useful in the medical treatment of a range of diseases, in nutritional supplements, nutricosmetics and in cosmetics.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: January 31, 2023
    Assignee: ABLIVA AB
    Inventors: Magnus Joakim Hansson, Alvar Grönberg, Mats Eskil Elmér, Mark Richard Farmery, Steven James Moss, Lee Robert Webster, Matthew Alan Gregory
  • Cell-permeable succinate compounds
    Patent number: 11147789
    Abstract: The present invention provides novel cell-permeable succinates and cell permeable precursors of succinateaimed at increasing ATP-production in mitochondria. The main part of ATP produced and utilized in the eukaryotic cell originates from mitochondrial oxidative phosphorylation, a process to which high-energy electrons are provided by the Kreb's cycle. Not all Kreb's cycle intermediates are readily permeable to the cellular membrane, one of them being succinate. The provision of the novel cell permeable succinates is envisaged to allow passage over the cellular membrane and thus the cell permeable succinates can be used to enhance mitochondrial ATP-output.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: October 19, 2021
    Assignee: ABLIVA AB
    Inventors: Eskil Elmer, Magnus Joakim Hansson, Karl Henrik Johannes Ehinger, Steven Moss
  • Use of sanglifehrin macrocyclic analogues as anticancer compounds
    Patent number: 10857150
    Abstract: The present invention relates to sanglifehrin macrocyclic analogues according to Formula (I), particularly for use in treatment of cancer, especially liver cancer.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: December 8, 2020
    Assignee: ABLIVA AB
    Inventors: Alvar Gronberg, Magnus Joakim Hansson, Matthew Alan Gregory, Steven James Moss